Shift In Drug Approval Process At FDA Under Trump? | WVIA

Shift In Drug Approval Process At FDA Under Trump?

Last Updated by NPR on

This week, the FDA did something rare: it reversed itself, and said it would no longer require further study of a drug for a rare disease. Instead, the FDA said the drug company could go ahead and seek approval of the drug with just the data from previous clinical trials. There have been other instances in recent months of the FDA allowing drugs to move through the approval process more quickly.

Adam Feuerstein (@adamfeuerstein), national biotech columnist for STAT, joins Here & Now‘s Meghna Chakrabarti to look at whether there’s a shift in how drugs are being regulated and approved at the FDA under President Trump and FDA Commissioner Scott Gottlieb.

Copyright 2017 NPR. To see more, visit

listenlive_fulllength.jpg cove_spacer.png
Now Playing on WVIA-FM



Undersea 'Banging Sounds' Not From Sub, Argentine Navy Says

First reports of the sounds picked up by surface ships briefly raised hopes that the missing ARA San Juan, with 44...

Germany's Merkel: New Elections Preferable To Minority Government

The chancellor says she's "very skeptical" of forming a minority government, something that hasn't happened in...

Poll: Majority of LGBTQ Americans Report Harassment, Violence Based On Identity

In the poll, LGBTQ people also reported numerous experiences of institutional discrimination — in jobs, equal pay...


healthybites_sidebar2.png reserve3.png artscene_header.png